Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $3.92, $1.17 better than the analyst estimate of $2.75. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $10 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2024 EPS of $16.10-$16.60, versus the consensus of $13.76. Eli Lilly & Co. sees FY2024 revenue of $45.4-46.6 billion, versus the consensus of $43.01 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold
• FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing